• Apollo Therapeutics

    Translating innovative science into therapeutic potential
  • Apollo Therapeutics

    Translating innovative science into therapeutic potential

  • Apollo Therapeutics

    Translating innovative science into therapeutic potential

1
/
3
/

Apollo People

  • DRUG DISCOVERY
  • INVESTMENT COMMITTEE
  • LLP COMMITTEE
  • SCIENTIFIC ADVISORY BOARD

The drug discovery team is lead by the CEO and are experienced in the discovery and development of pharmaceuticals from a range of modalities and therapeutic indications.  The drug discovery team will work with academic scientist to identify the best translational targets and to prosecute and deliver a pipeline of targets for licensing

MORE

The investment committee has the sole responsibility for endorsing the projects, project plans, costs, timelines and licensing strategy proposed by the drug discovery team

MORE

The members of the Limited Liability partnership group will meet annually and be responsible for corporate governance of Apollo Therapeutics activities

MORE

Eminent scientists and leaders from the academic and pharmaceutical companies involved in establishing Apollo will be consulted and advise on the scientific and strategic direction of Apollo Therapeutics

MORE

Apollo News

Apollo Therapeutics News & Press Releases

Why can’t we cure the common cold?

13th October 2017
The common cold has the twin distinction of being both the world’s most widespread infectious disease and one of the most elusive… READ THE FULL GUARDIAN ARTICLE HERE

Apollo Therapeutics Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

2nd August 2017
Stevenage, 12 June 2017: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, is pleases to announce that it has been shortlisted as a finalist in the ‘UK Life Science Spin-Out of the Year’ category of the Biotech and Money 2017 Awards. Apollo was selected as a finalist for the award following its launch last year from AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge. Apollo supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases. Since its launch, Apollo has approved funding for and launched initial discovery projects across antitrypsin deficiency, retinal degeneration, pulmonary arterial hypertension and the enhancement of autologous and in vivo T-cell therapies. The winners in each category are determined 50% by this online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September. Voting is now open.
News Press Release

Funding of four initial projects and operational update

22nd February 2017
First four drug discovery programmes now launched in collaboration with academics at all three partner universities – spanning a variety of disease areas and drug modalities Recruited highly experienced Project Directors with track records of delivering project success within big pharma More than £8.5m committed to projects so far from a total budget of £40m Stevenage, [22 February, 2017]: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first of its drug discovery programmes in collaboration with academics at each of its partner universities. Apollo Therapeutics was established in January 2016 by AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge. It supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases. After evaluating initial opportunities across all three universities, Apollo has approved funding for and launched its first four drug discovery projects: A small molecule discovery programme to treat alpha1 antitrypsin deficiency, a genetic disorder affecting the lungs and liver, with Dr Ravi Mahadeva, University of Cambridge and Addenbrooke’s Hospital A cell therapy for the treatment of retinal degeneration, which is a major cause of vision loss and blindness, with Prof Astrid Limb and Prof Sir Peng Khaw at the UCL Institute of Ophthalmology A small and large molecule discovery programme for the treatment of pulmonary arterial hypertension, a condition affecting the cardiovascular system, with Prof Martin Wilkins and Prof Lan Zhao, Imperial College London A project to enhance the efficacy and persistence of autologous and in vivo T-cell therapies, with Prof Randall Johnson, University of Cambridge These initial projects represent novel and compelling drug discovery projects, emerging from academic research in areas of high medical need for which Apollo’s Drug Discovery Team saw a clear route to value creation. A total of £8.5m has been committed in milestoned project plans.Two further projects are currently being finalised, with multiple others in the evaluation process across all three academic institutions. The recruitment of the Drug Discovery Team Project Directors is now complete with Dr Paul Hamblin, Dr Darren Cawkill and Dr Nadine Clemo accepting positions under the leadership of CEO, Dr Richard Butt. Bringing more than 60 years’ combined experience to running and delivering projects within industry, across a variety of technology platforms and therapy areas, the team is well positioned to work with academic scientists to identify drug targets and design innovative drug discovery programmes through key milestones for potential future licensing. Apollo’s collaborative model is working well with its technology transfer partners – Cambridge Enterprise, Imperial Innovations and UCL Business – providing valuable support in sourcing opportunities from within their respective academic institutions. Industry partners AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation are also contributing both expertise and internal resources to enable project evaluation and execution. Dr Richard Butt, CEO of Apollo Therapeutics, commented:

A New Era of Collaboration

27th September 2016
A new era of collaboration: why Apollo Therapeutics succeed where other translational funding mechanisms have failed? Ian Tomlinson, Chairman at Apollo Therapeutics, talks to Biotech and Money about the newly formed consortium fund http://www.biotechandmoney.com/blog/2016/05/03/a-new-era-of-collaboration-why-apollo-therapeutics-succeed-where-other-translational-funding-mechanisms-have-failed  
Load more

About Apollo

Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.